Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Recruiting
Observational Study
Optic Neuritis
Transverse Myelitis
Acute Disseminated Encephalomyelitis
Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorder
Anti-NMDAR Encephalitis
Anti-GAD65 Associated Autoimmune Encephalitis
Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
Anti-Lgi-1 Associated Autoimmune Encephalitis
Anti-CASPR-2 Associated Autoimmune Encephalitis
Anti-GABAR-1/2 Associated Autoimmune Encephalitis
Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
Hashimoto Encephalitis
CNS Vasculitis
CNS Sarcoidosis
CNS Lupus
Rasmussen Encephalitis
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 36
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- University of Bern · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Ge…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.
* Written informed consent by patients (and/or legal representative(s), if applicable)
* Optic Neuritis
* …
Contacts